Matinas Biopharma Holdings Inc (MTNB) recently have taken one step ahead with the beta value of 1.63

Matinas Biopharma Holdings Inc (AMEX: MTNB) started the day on Wednesday, with a price decrease of -1.67% at $0.18, before settling in for the price of $0.19 at the close. Taking a more long-term approach, MTNB posted a 52-week range of $0.11-$0.89.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 1874.16%. Meanwhile, its Annual Earning per share during the time was 7.12%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 0.00%. This publicly-traded company’s shares outstanding now amounts to $250.82 million, simultaneously with a float of $243.50 million. The organization now has a market capitalization sitting at $45.80 million. At the time of writing, stock’s 50-day Moving Average stood at $0.2418, while the 200-day Moving Average is $0.2271.

Matinas Biopharma Holdings Inc (MTNB) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Matinas Biopharma Holdings Inc’s current insider ownership accounts for 2.92%, in contrast to 10.30% institutional ownership.

Matinas Biopharma Holdings Inc (AMEX: MTNB) Trading Performance Indicators

Let’s observe the current performance indicators for Matinas Biopharma Holdings Inc (MTNB). It’s Quick Ratio in the last reported quarter now stands at 5.93. The Stock has managed to achieve an average true range (ATR) of 0.02. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 41.64.

In the same vein, MTNB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.11, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be -0.11 at the market close of one year from today.

Technical Analysis of Matinas Biopharma Holdings Inc (MTNB)

If we take a close look at the recent performances of Matinas Biopharma Holdings Inc (AMEX: MTNB), its last 5-days Average volume was 1.13 million that shows plunge from its year to date volume of 1.38 million. During the previous 9 days, stock’s Stochastic %D was recorded 37.34% While, its Average True Range was 0.0165.

Raw Stochastic average of Matinas Biopharma Holdings Inc (MTNB) in the period of the previous 100 days is set at 4.85%, which indicates a major fall in contrast to 22.22% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 28.16% that was lower than 117.32% volatility it exhibited in the past 100-days period.